A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge (ChiCTR) - Oct 16, 2026 - P2 | N=43 | Recruiting | Sponsor: hunan cancer hospital; hunan cancer hospital
New P2 trial • Oncology • Ovarian Cancer • Solid Tumor
|